Vendor comparison · 2026
Cerebrolysin vendors: 1 compared on COAs and price
OtherEvidence tier
Substantial published literature
666 publications over 53 years · trials not yet curated
- Vendors carrying it
- 1
- 1 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $1.27
- peer median $1.27
- Publications located
- 666
- researched since 1973
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Cerebrolysin certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $1.27 per mg at Evo Labs Research, against a peer median of $1.27. 1 vendor carrying Cerebrolysin is compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Cerebrolysin
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Evo Labs Research | 72.387% | $1.27 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Cerebrolysin is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Cerebrolysin names a laboratory this index could identify.
Every certificate record
No certificate record for Cerebrolysin is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1973 — 53 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
666 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Cerebrolysin?
A peptide preparation derived from porcine brain tissue, studied in stroke, dementia and traumatic brain injury. It is approved as a medicine in some countries but not in the United States.
Studied in published research for stroke, dementia and traumatic brain injury.
Regulatory status
Cerebrolysin is approved as a medicine in some countries but not in the United States. Products listed here are labeled by their vendors for laboratory research use only, and nothing here is medical advice.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Cerebrolysin for acute ischaemic stroke — The Cochrane database of systematic reviews (2023)
Peer-reviewed article indexed in PubMed, published in The Cochrane database of systematic reviews (2023).
- Cerebrolysin for vascular dementia — The Cochrane database of systematic reviews (2019)
Peer-reviewed article indexed in PubMed, published in The Cochrane database of systematic reviews (2019).
- Cerebrolysin for acute ischaemic stroke — The Cochrane database of systematic reviews (2020)
Peer-reviewed article indexed in PubMed, published in The Cochrane database of systematic reviews (2020).
- Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis — Brain sciences (2023)
Peer-reviewed article indexed in PubMed, published in Brain sciences (2023).
- Cerebrolysin for acute ischaemic stroke — The Cochrane database of systematic reviews (2017)
Peer-reviewed article indexed in PubMed, published in The Cochrane database of systematic reviews (2017).
- Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis — Journal of clinical medicine (2023)
Peer-reviewed article indexed in PubMed, published in Journal of clinical medicine (2023).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.